Genzyme Completes Bioenvision Takeover
This article was originally published in The Pink Sheet Daily
Executive Summary
Extended stockholder vote supports merger, with 67 percent of shares voted in favor of $345 million deal.
You may also be interested in...
Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year
Enzyme-replacement sales strong as firm builds on renal franchise.
Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year
Enzyme-replacement sales strong as firm builds on renal franchise.
Genzyme Aims To File Clolar Label Expansion For Acute Myelogenous Leukemia In Mid-2008
The firm projects global sales of clofarabine for blood cancers to peak at $600 million over ten years, CEO Termeer says.